Clinical Trial Update: A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating sirukumab (CNTO 136) subcutaneously in active rheumatoid arthritis patients on DMARD therapy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Sirukumab (sirukumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2018-01-11